Regional hyperthermia in high-risk soft tissue sarcomas

Current Opinion in Oncology

Volumn 20, Issue 4, 2008, Pages 438-443

  Issels, Rolf D ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

High risk soft tissue sarcoma; Preoperative and postoperative treatment strategies; Regional hyperthermia

Indexed keywords

DACARBAZINE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; MESNA; ANTINEOPLASTIC AGENT;

CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CLINICAL RESEARCH; EXPERIMENTAL THERAPY; EXTERNAL BEAM RADIOTHERAPY; HUMAN; HYPERTHERMIA; HYPERTHERMIC THERAPY; INTRAOPERATIVE RADIOTHERAPY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSTOPERATIVE CARE; PREOPERATIVE CARE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; RETROPERITONEAL SARCOMA; RETROSPECTIVE STUDY; REVIEW; RISK FACTOR; SOFT TISSUE SARCOMA; UNSPECIFIED SIDE EFFECT; CLINICAL TRIAL; SARCOMA;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HUMANS; HYPERTHERMIA, INDUCED; SARCOMA;

EID: 47249140485     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e3283025e50     Document Type: Review

References (29)

1. Kattan MW, Leung DH, Brennan MF. Postoperative nomogram for 12-year sarcoma-specific death. J Clin Oncol 2002; 20:791-796.
2. Ferrari A, Miceli R, Casanova M, et al. Adult-type soft tissue sarcomas in paediatric age: a nomogram-based prognostic comparison with adult sarcoma. Eur J Cancer 2007; 43:2691-2697. The variables known to have a prognostic role in adult-type STS are relevant also in children.
3. Pisters PW, Leung DH, Woodruff J, et al. Analysis of prognostic factors in 1041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol 1996; 14:1679-1689.
4. Mariani L, Miceli R, Kattan MW, et al. Validation and adaptation on a nomogram for predicting the survival of patients with extremity soft tissue sarcoma using a three-grade system. Cancer 2005; 103:402-408.
5. Stojadinovic A, Leung DHY, Allen P, et al. Primary adult soft tissue sarcoma: time-dependent influence on prognostic variables. J Clin Oncol 2002; 20:4344-4352.
6. Trovik CS, Bauer HCF, Alvegard TA, et al. Surgical margins, local recurrence and metastasis in soft tissue sarcomas: 559 surgically-treated patients from the Scandinavian Sarcoma Group register. Eur J Cancer 2000; 36:710-716.
7. Stojadinovic A, Leung DHY, Hoos A, et al. Analysis of the prognostic significance of microscopic margins in 2084 localized primary adult soft tissue sarcomas. Ann Surg 2002; 235:424-433.
8. Gronchi A, Casali PG, Mariani L, et al. Status of surgical margins and prognosis in adult soft tissue sarcomas of the extremities: a series of 911 consecutive patients treated at a single institution. J Clin Oncol 2005; 23:96-104.
9. Eilber FC, Rosen G, Nelson SD, et al. High-grade extremity soft tissue sarcomas. Factors predictive of local recurrence and its effect on morbidity and mortality. Ann Surg 2003; 237:218-226.
10. Gronchi A, Miceli R, Fiore M, et al. Extremity soft tissue sarcoma: adding to the prognostic meaning of local failure. Ann Surg Oncol 2007; 14:1583-1590. Interesting retrospective analysis on the outcome of patients with local relapse operated at a single institution. The prognostically adverse effect of local relapse was greater in patients in whom the aggressiveness of the disease could be its main explanation.
11. Lewis JJ, Leung D, Woodruff JM, et al. Retroperitoneal soft-tissue sarcoma: analysis of 500 patients treated and followed at a single institution. Ann Surg 1998; 228:355-365.
12. Stoeckle E, Coindre JM, Bonvalot S, et al. Prognostic factors in retroperitoneal sarcoma: a multivariate analysis of a series of 165 patients of the French Cancer Center Federation Sarcoma Group. Cancer 2001; 92:359-368.
13. Pham TH, Iqbal CW, Zarroug AE, et al. Retroperitoneal sarcomas in children: outcomes from an institution. J Pediatr Surg 2007; 42:829-833. In this retrospective analysis performed at the Mayo Clinic, the authors focus on prognostic significance of grade and resectability for the 5-year disease-specific survival rates of children with advanced locoregional involvement of abdomino-pelvic structures.
14. Stojadinovic A, Yeh A, Brennan MF. Completely resected recurrent soft tissue sarcoma: primary anatomic site governs outcomes. J Am Coll Surg 2002; 1984:436-447.
15. Gutierrez JC, Perez EA, Moffat FL, et al. Should soft tissue sarcomas be treated at high-volume centres? Ann Surg 2007; 245:952-958. Soft-tissue sarcoma should be treated in high-volume centres to reduce inadequate local control, surgical sequelae and eventually death from the disease.
16. Gronchi A, Casali PG, Fiore M, et al. Retroperitoneal soft tissue sarcomas. Patterns of recurrence in 167 patients treated at a single institution. Cancer 2004; 100:2448-2455.
17. Ballo MT, Zagars GK, Pollock RE, et al. Retroperitoneal soft tissue sarcoma: an analysis of radiation and surgical treatment. Int J Radiat Oncol Biol Phys 2007; 67:158-163. The retrospective analysis from the MDACC provides detailed information on the clinical outcome of patients with localized retroperitoneal STS treated with complete surgical resection and radiation. Critical discussion on the possible benefit of preoperative and postoperative radiation therapy in selected patients with high-risk retroperitoneal disease due to the lack of a randomized trial.
18. Gronchi A, Olmi P, Casali PG. Combined modalities approach forlocalized adult extremitysoft-tissue sarcoma. Expert Rev Anticancer Ther 2007;7:1135-1144. This excellent review discusses all aspects and results of continued treatment modalities for adult extremity STS. The authors also focus on new perspectives of histology-driven therapy.
19. Grobmyer SR, Make RG, Demetri GD, et al. Neoadjuvant chemotherapy for primary high-grade extremity soft tissue sarcoma. Ann Oncol 2004; 15:1667-1672.
20. Kraybill WG, Harris J, Spiro IJ, et al. Phase II study of neoadjuvant chemotherapy and radiation therapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514. J Clin Oncol 2006; 24:619-625.
21. Pisters PWT. Preoperative chemotherapy and split-course radiation therapy for patients with localized soft tissue sarcomas: home run, base hit, or strike out? J Clin Oncol 2006; 24:549-551.
22. Gortzak E, Azzarelli A, Buesa J, et al. A randomised phase II study on neoadjuvant chemotherapy for 'high-risk' adult soft-tissue sarcoma. Eur J Cancer 2001; 37:1096-1103.
23. Wust P, Hildebrandt B, Sreenivasa G, et al. Hyperthermia in combined treatment of cancer. Lancet Oncol 2002; 3:487-497.
24. Issels RD, Prenninger SW, Nagele A, et al. Ifosfamide plus etoposide combined with regional hyperthermia in patients with locally advanced sarcomas: a phase II study. J Clin Oncol 1991; 8:1818-1829.
25. Lagendijk JJ, van Rhoon GC, Hornsleth SN, et al. ESHO quality assurance guidelines for regional hyperthermia. Int J Hyperthermia 1998; 14:125-133.
26. Issels RD, Abdel-Rahman S, Wendtner CM, et al. Neoadjuvant chemotherapy combined with regional hyperthermia (RHT) for locally advanced primary or recurrent high-risk soft tissue sarcomas (HR-STS) of adults: long-term results of a phase II study. Eur J Cancer 2001; 37:1599-1608. survival were also significantly better for the combined treatment arm. Conclusion During the last decade, some progress has been made in the use of combined modality treatment strategies. Owing to the complexity of high-risk STSs, patients should be best treated in referral centres where a dedicated and experienced multidisciplinary team is available. The approach of multimodality treatment using RHT combined systemic chemotherapy within a preoperative and postoperative strategy described in the present study is an innovative treatment option. The technology is safe and effective. Today, RHT can be routinely administered, but only at a few specialized clinical ESHO centres. In the treatment concept for high-risk STS, the potential of RHT to increase the chemotherapeutic effect seems to be proven, but surgery followed by radiotherapyis still the corner stone for best local free control. The employment of RHT in combination with systemic chemotherapy has been performed and successfully tested in consecutive phase II studies, finally demonstrating a benefit for high-risk STS patients in a large phase III randomized trial, both in terms of local control and disease-free survival. RHT seems to offer an appropriate treatment option for high-risk STS, where local control is difficult to achieve and death may result from inoperable local disease progression.
27. Wendtner CM, Abdel-Rahman S, Baumert J, et al. Treatment of primary, recurrent or inadequately resected high-risk soft tissue sarcomas (HR-STS) of adults: results of a phase II pilot study (RHT-95) of neoadjuvant chemotherapy combined with regional hyperthermia. Eur J Cancer 2001; 37:1609-1616.
28. Wendtner CM, Abdel-Rahman S, Krych M, et al. Response to neoadjuvant chemotherapy combined with regional hyperthermia predicts long-term survival for adult patients with retroperitoneal and visceral high-risk soft tissue sarcomas. J Clin Oncol 2002; 20:3156-3164.
29. Issels RD, Lindner LH, Wust P, et al. Regional hyperthermia (RHT) improves response and survival when combined with systemic chemotherapy in the management of locally advanced, high grade soft tissue sarcomas (STS) of the extremities, the body wall and the abdomen: a phase III randomised prospective trial (EORTC-ESHO Intergroup trial) [abstract 10009]. J Clin Oncol 2007; 25 (18S):547s. First report of phase III results that prove a significant benefit for high-risk STSs by the addition of RHT.